Loading
A phase 2/3 trial of Trastuzumab brengitecan, Pertuzumab, Docetaxel in her2-positive breast cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.
A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer is a phase 2/3 interventional study registered as NCT06891833 by Sichuan Baili Pharmaceutical Co., Ltd., with 985 participants planned, started 2025-06-05 and due to reach its primary completion in 2028-12. Interventions recorded: BL-M07D1, Pertuzumab, docetaxel, carboplatin, trastuzumab. Conditions listed: HER2-positive Breast Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Trastuzumab brengitecan, Pertuzumab, SystImmune / Sichuan Biokin, Trastuzumab.
Shares Trastuzumab brengitecan, Pertuzumab, SystImmune / Sichuan Biokin, Docetaxel.
Shares Pertuzumab, Trastuzumab, Docetaxel, HER2-positive breast cancer.
Shares Trastuzumab brengitecan, Early HER2-positive breast cancer, SystImmune / Sichuan Biokin, HER2-positive breast cancer.
Shares Early HER2-positive breast cancer, Pertuzumab, Trastuzumab, Docetaxel.
Shares Pertuzumab, Trastuzumab, Docetaxel, HER2-positive breast cancer.
Shares Early HER2-positive breast cancer, Pertuzumab, HER2-positive breast cancer, Monoclonal antibodies.
Shares Early HER2-positive breast cancer, Pertuzumab, Trastuzumab, HER2-positive breast cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/